There are currently 2868 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Pre-exposure Prophylaxis (PrEP) Adherence Intervention for Women with Substance Use Disorders
NCT06158607
Recruiting
The goal of this clinical trial is to test an addiction-clinic based behavioral intervention for increasing PrEP uptake and adherence among women who engage in high-risk sexual behaviors and problematic substance use. The main question it aims to answer is: • If the integrated intervention increase PrEP uptake and adherence compared to standard treatment Participants will * receive provision of PrEP information through 4 counseling sessions * prevention navigation * receive nurse practitioner... Read More
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
12/27/2024
Locations: Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Substance Use
Register for Updates
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
NCT02915198
Recruiting
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in Veterans who have pre-diabetes and heart or blood vessel problems.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas
Conditions: Prediabetic State, Atherosclerosis, Metformin
Register for Updates
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
NCT05137665
Recruiting
The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/26/2024
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease
Register for Updates
ADELANTE: a Randomized Controlled Trial to Improve Engagement in Care for Latinos with HIV
NCT06274632
Recruiting
The goal of this study is to test the effectiveness of ADELANTE on viral suppression among Latinos with HIV and viral non-suppression. Participants will receive ADELANTE (5-session, community health worker-delivered, problem-solving intervention) or enhanced care condition (ECC, 5 reminder phone calls). We will evaluate the overall effectiveness of ADELANTE compared with ECC on rates of viral suppression and emergency room visits and hospitalizations. Our hypothesis is that ADELANTE participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2024
Locations: Baylor College of Medicine, Houston, Texas
Conditions: HIV/AIDS
Register for Updates
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy
NCT05696717
Recruiting
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).
Gender:
ALL
Ages:
30 years and above
Trial Updated:
12/20/2024
Locations: Theravance Biopharma Investigative Site, Houston, Texas
Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Register for Updates
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
NCT06470243
Recruiting
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic). Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by kill... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Lyndon Baines Johnson General Hospital, Houston, Texas +2 locations
Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
The ENCIRCLE Trial
NCT04153292
Recruiting
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: HCA Houston Healthcare Medical (SCRI), Houston, Texas +1 locations
Conditions: Mitral Regurgitation, Mitral Valve Insufficiency
Register for Updates
Study Comparing Tapinarof Cream 1% to VTAMA ® (Tapinarof Cream 1%) in the Treatment of Plaque Psoriasis
NCT06742957
Recruiting
To compare the safety and efficacy of the test (Tapinarof Cream 1%), placebo (vehicle cream) and reference VTAMA® (Tapinarof Cream 1%) treatments to demonstrate clinical equivalence in patients with plaque psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Site 12117, Houston, Texas
Conditions: Plaque Type Psorisis
Register for Updates
Melodi Matrix™ in Breast Reconstruction
NCT06027996
Recruiting
Prospective, multicenter, randomized, controlled trial evaluating the safety and effectiveness of an absorbable antibacterial matrix device in two stage prepectoral alloplastic breast reconstruction.
Gender:
FEMALE
Ages:
22 years and above
Trial Updated:
12/19/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Reconstruction
Register for Updates
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, with or Without Monoclonal Antibodies in Advanced Solid Tumors
NCT06241456
Recruiting
This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced solid tumors. The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT825 in indication-specific cohorts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor
Register for Updates
Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
NCT05639933
Recruiting
The goal of this clinical trial is to learn about HT-001 Topical Gel for treatment of EGFR inhibitor-induced skin toxicities. The main questions it aims to answer are: * Determine the therapeutic effect of HT-001 for treatment of patients who develop acneiform rash undergoing Epidermal Growth Factor inhibitor (EGFRI) therapy using the acneiform rash investigator's global assessment scale \[ARIGA\] * Evaluate the safety of HT-001 during treatment Participants will apply HT-001 Gel once per day... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
Register for Updates
Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135
Recruiting
This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subjects will start by receiving ruxolitinib alone in the run-in period. Those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: U.T. MD Anderson Cancer Center, Houston, Texas
Conditions: Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF
Register for Updates